Are Changes Underway at Valeant?
Valeant Pharmaceuticals Chief Executive Officer Michael Pearson is taking a medical leave of absence, putting management of the embattled drugmaker in the hands of a team of executives. Bloomberg's Drew Armstrong has the latest on "Bloomberg ‹GO›." Bloomberg Editor-in-Chief Emeritus Matthew Winkler also comments. (Source: Bloomberg)